DEFA14A: HSPT Amends Proxy for SL Bio Merger Vote

Horizon Space Acquisition II Corp. filed an 8-K to correct and clarify proxy statement details for its upcoming business combination vote with SL BIO Ltd., focusing on redemption procedures and contact information.

Summary

• Horizon Space Acquisition II Corp. (HSPT) filed a Form 8-K to amend its definitive proxy statement, originally filed on January 13, 2026.
• The amendments primarily correct and replace references to the trust agent and transfer agent, along with their corresponding contact information.
• The filing clarifies the procedures for public shareholders to exercise their redemption rights in connection with the proposed business combination with SL BIO Ltd. (SL Bio).
• The Extraordinary General Meeting to vote on the Business Combination is scheduled for February 3, 2026.
• The deadline for shareholders to make a Redemption Election is 5:00 pm Eastern Time on January 30, 2026.
• Wilmington Trust, National Association is confirmed as the trustee for the Trust Account.
• Advantage Proxy, Inc. is identified as HSPT's proxy solicitor, and VStock Transfer, LLC is the transfer agent for redemptions.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive due to the clarification of important shareholder information, which enhances transparency. However, the need for an amendment indicates initial inaccuracies, and the highlighted risks associated with redemptions are standard but notable for SPAC transactions.

Positives

• The company is proactively correcting and clarifying important procedural information, enhancing transparency for shareholders.
• Clearer instructions for redemption rights and updated contact information for key agents (proxy solicitor, transfer agent) should reduce shareholder confusion.

Negatives

• The necessity of filing an amendment indicates initial inaccuracies or omissions in the definitive proxy statement.
• Shareholders opting for physical share certificates for redemption may face significant delays (at least two weeks), potentially causing them to miss the January 30, 2026 deadline.
• A nominal cost of $100 may be charged by the transfer agent to tendering brokers, which could be passed on to redeeming shareholders.

Risks

• Significant redemptions by HSPT shareholders could lead to a less liquid trading market for PubCo Ordinary Shares after the business combination.
• Substantial redemptions could result in PubCo failing to meet Nasdaq listing standards, which is a condition for the consummation of the Business Combination.
• The inability to complete the proposed Business Combination due to various factors, including failure to receive required security holder approvals or other closing conditions.
• The inability to recognize the anticipated benefits of the proposed Business Combination, potentially affected by the amount of cash available following redemptions.
• Costs related to the proposed Business Combination could impact the combined company's financial position.
• SL Bio's or the combined company's limited operating history presents inherent business risks.
• Challenges in identifying and integrating future acquisitions could hinder growth.
• General economic and market conditions may negatively impact demand for the combined company's products.

Future Outlook

The filing includes forward-looking statements regarding the potential advantages and expected growth of the combined company, its cash position post-closing, and the ability of HSPT and SL Bio to consummate the proposed Business Combination and its timing. These statements are subject to various risks and uncertainties, including those detailed in HSPT's previous SEC filings, such as the impact of redemptions, market conditions, and the ability to meet stock exchange listing standards.

Industry Context

This filing represents a routine procedural update within the SPAC (Special Purpose Acquisition Company) merger process. Such amendments are common to ensure full compliance with SEC disclosure requirements and to provide accurate information to shareholders ahead of a critical vote. The risks highlighted, particularly concerning redemptions and their potential impact on liquidity and listing standards, are typical considerations in SPAC transactions, reflecting the unique structure and shareholder optionality inherent in these deals.

Stakeholder Impact

• **Shareholders**: Provided with corrected and clarified information regarding the business combination vote and redemption rights, which is crucial for their investment decisions. There is a potential for a less liquid trading market and failure to meet Nasdaq listing standards if redemptions are significant.
• **Investment Professionals**: Receive updated procedural details for the SPAC merger, aiding in their analysis and advice to clients.
• **Regulatory Authorities**: The filing demonstrates compliance with SEC disclosure requirements by correcting previously filed information.

Next Steps

• Shareholders should review the amended definitive proxy statement for the corrected information.
• Shareholders requiring additional materials must request them by January 27, 2026.
• Shareholders intending to redeem their shares must submit a written request and deliver their shares to the transfer agent by the Redemption Deadline of January 30, 2026.
• The Extraordinary General Meeting will proceed as scheduled on February 3, 2026, for shareholders to vote on the Business Combination.
• The Business Combination between HSPT and SL Bio is expected to be completed following shareholder approval and satisfaction of other closing conditions.

Key Dates

Keywords

HSPT, SL Bio, SPAC, Business Combination, Merger, Proxy Statement, Redemption Rights, SEC Filing, Form 8-K, Nasdaq Listing